1.1 List of Tables
1.2 List of Figures

2 Respiratory Syncytial Virus: Executive Summary
2.1 Strong Growth Projected for the RSV Market from 2018 to 2028
2.2 Both Large and Small Developers Are Focused on the Untapped RSV Therapeutics Market
2.3 The Market for Cost-Effective RSV Prophylaxis Is Highly Competitive
2.4 Despite Projected Entrance of Novel Products, Opportunities Remain for Current and Future Players
2.5 Future RSV Management Strategies Will Include Multiple Products
2.6 What Do Physicians Think?

3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology

5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used and Not Used
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for RSV Hospitalized Population (2018-2028)
5.5.1 Number of Hospitalized Adults with Positive RSV Test
5.5.2 Number of Children Hospitalized for RSV
5.6 Epidemiological Forecast for RSV Prophylactic Population (2018-2028)
5.6.1 Number of Preterm Births by Gestational Age
5.6.2 Premature Infants with CLD
5.6.3 Number of Live Births with Hemodynamically Significant Heart Disease
5.6.4 Diagnosed Prevalent Cases of DMD
5.6.5 Number of Diagnosed Prevalent Cases of SMA
5.6.6 Number of Third Trimester Pregnant Women
5.6.7 Number of Adults Living in Nursing Homes/Long-Term Care Institutions
5.7 Discussion
5.7.1 Epidemiological Forecast Insight
5.7.2 Limitations of Analysis
5.7.3 Strengths of Analysis

6 Current Treatment Options
6.1 Overview

7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Improved Cost-Effective Passive Prophylaxis
7.2.1 Unmet Need
7.2.2 Gap Analysis and Opportunity
7.3 Prophylactic Vaccines
7.3.1 Unmet Need
7.3.2 Gap Analysis and Opportunity
7.4 Effective Therapeutic Antivirals
7.4.1 Unmet Need
7.4.2 Gap Analysis and Opportunity
7.5 Increased Research and Awareness of Long-term Sequela
7.5.1 Unmet Need
7.5.2 Gap Analysis and Opportunity

8 R&D Strategies
8.1 Overview
8.1.1 Development of RSV Antiviral Therapeutics with Diverse Mechanisms of Action
8.1.2 Leveraging Novel Vaccine Technologies and Strategies
8.1.3 Development of Prophylactic Antibodies with Improved Dosing and Efficacy
8.2 Clinical Trials Design
8.2.1 Clinical Trials Design of Pipeline Prophylactics for Maternal Immunization
8.2.2 Clinical Trials Design of Pipeline Prophylactics for Pediatric Immunization
8.2.3 Clinical Trials Design of Pipeline Prophylactics for Adult Immunization
8.2.4 Demonstration of Efficacy for Fusion Inhibitor Antivirals
8.2.5 Demonstration of Efficacy for Replication Inhibitor Antivirals

9 Pipeline Assessment
9.1 Overview
9.1.1 Recently Discontinued Pipeline Products
9.2 Innovative Early-Stage Approaches
9.3 Other Drugs in Development

10 Pipeline Valuation Analysis
10.1 Clinical Benchmark of Key Pipeline Drugs
10.1.1 Therapeutic Agents
10.1.2 Prophylactic Agents
10.2 Commercial Benchmark of Key Pipeline Drugs
10.2.1 Therapeutic Agents
10.2.2 Prophylactic Agents
10.3 Competitive Assessment
10.3.1 Therapeutic Agents
10.3.2 Prophylactic Agents
10.4 Top-Line 10-Year Forecast
10.4.1 US
10.4.2 5EU
10.4.3 Japan

11 Appendix

List of Tables
Table 1: Respiratory Syncytial Virus: Key Metrics in the 7MM
Table 2: Risk Factors for Severe RSV
Table 3: Treatment Guidelines for RSV
Table 4: Leading Treatments for RSV, 2019
Table 5: Clinical Trial Designs for RSV Vaccines for Maternal Immunization
Table 6: Clinical Trial Designs for RSV Prophylactics for Pediatric Patients
Table 7: Clinical Trial Designs for RSV Prophylactics for Adult Patients
Table 8: Clinical Trial Designs for RSV Fusion Inhibitor Therapeutics
Table 9: Clinical Trial Designs for RSV Replication Inhibitor Therapeutics
Table 10: Innovative Early Stage Approaches for RSV, 2019
Table 11: Drugs in Development for RSV, 2019
Table 12: Clinical Benchmark of Key Pipeline Therapeutics
Table 13: Clinical Benchmark of Key Pipeline Prophylactics - RSV mAbs
Table 14: Clinical Benchmark of Key Pipeline Prophylactics - RSV Vaccines
Table 15: Commercial Benchmark of Key Pipeline Therapeutics
Table 16: Commercial Benchmark of Key Pipeline Prophylactics - RSV mAbs
Table 17: Commercial Benchmark of Key Pipeline Prophylactics - RSV Vaccines
Table 18: Key Events Impacting Sales for RSV, 2018-2028
Table 19: RSV Market - Global Drivers and Barriers, 2018-2028
Table 20: Key Historical and Projected Launch Dates for RSV
Table 21: Key Historical and Projected Patent Expiry Dates for RSV
Table 22: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global Sales Forecast by Country for RSV in 2018 and 2028
Figure 2: Competitive Assessment of Pipeline Therapeutics Benchmarked Against Janssen's Experimental Antiviral JNJ-53718678
Figure 3: Competitive Assessment of the Marketed and Pipeline Prophylactics Benchmarked Against AstraZeneca's Synagis
Figure 4: Structure of the Human RSV Virion
Figure 5: Replication Cycle of RSV
Figure 6: 7MM, Children, Boys and Girls, 0-2 Years Old, Confirmed RSV Hospitalizations, N, 2008-2018
Figure 7: 7MM, Rate of Preterm Births (per 1,000 Live Births), 2008-2018
Figure 8: 7MM, Percentage of Adults Living in Long-Term Care, Ages ?55 Years, 2008-2018
Figure 9: 7MM, Sources Used to Forecast the Number of Adults Hospitalized Who Test Positive for RSV, 2018-2028
Figure 10: 7MM, Sources Used to Forecast the Number of Children Hospitalized with Confirmed RSV
Figure 11: 7MM, Sources Used to Forecast the Number of Preterm Births
Figure 12: 7MM, Sources Used to Forecast the Number of Preterm Births with CLD, 2018-2028
Figure 13: 7MM, Sources Used to Forecast the Number of Live Births with Hemodynamically Significant Heart Disease
Figure 14: 7MM, Sources Used to Forecast Diagnosed Prevalent Cases of DMD
Figure 15: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SMA
Figure 16: 7MM, Sources Used to Forecast the Number of Third Trimester Pregnancies
Figure 17: 7MM, Sources Used to Forecast the Number of Adults Living in Long-Term Care
Figure 18: 7MM, Number of Hospitalized Adults, Ages ?60 Years, with Positive RSV Test, Men and Women, 2018
Figure 19: 7MM, Number of Children, Ages 0-2 Years, Boys and Girls, Hospitalized for RSV, 2018
Figure 20: 7MM, Number of Preterm Births by Gestational Age, N, 2018
Figure 21: 7MM, Number of Preterm Infants with CLD, N, 2018-2028
Figure 22: 7MM, Number of Live Births with Hemodynamically Significant Heart Disease, 2018-2028
Figure 23: 7MM, Diagnosed Prevalent Cases of DMD in Boys, Ages 0-2 Years, 2018-2028
Figure 24: 7MM, Diagnosed Prevalent Cases of SMA, Boys and Girls, Ages 0-2 Years, 2018-2028
Figure 25: 7MM, Number of Third Trimester Pregnant Women, N, 2018-2028
Figure 26: 7MM, Number of Adults Living in Care Institutions, Ages ?55 Years, N, 2018-2028
Figure 27: Unmet Needs and Opportunities in RSV
Figure 28: Overview of the Development Pipeline in RSV
Figure 29: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for RSV in the 7MM During the Forecast Period
Figure 30: Competitive Assessment of Pipeline Antivirals
Figure 31: Competitive Assessment of Pipeline Prophylactics Benchmarked Against the Current SOC
Figure 32: Global (7MM) Sales Forecast by Country for RSV in 2018 and 2028
Figure 33: Global Sales Forecast by Product for RSV in 2028
Figure 34: Therapeutic Sales Forecast by Product for RSV in the US from 2018 to 2028
Figure 35: Prophylactic Sales Forecast by Class for RSV in the US from 2018 to 2028
Figure 36: Therapeutic Sales Forecast by Product for RSV in the 5EU from 2018 to 2028
Figure 37: Prophylactic Sales Forecast by Class for RSV in the 5EU from 2018 to 2028
Figure 38: Therapeutic Sales Forecast by Product for RSV in Japan from 2018 to 2028
Figure 39: Prophylactic Sales Forecast by Class for RSV in Japan from 2018 to 2028

Companies Mentioned
- Ark Biosciences
- AstraZeneca
- Bavarian Nordic
- Enanta Pharmaceuticals
- GlaxoSmithKline
- Janssen
- Merck & Co.
- Novavax
- Pfizer
- Pulmocide
- ReViral